Impact of unreported HIV‐1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non‐nucleoside inhibitors
暂无分享,去创建一个
S. Lo Caputo | F. Mazzotta | L. Scudeller | C. Torti | G. Carosi | G. Angarano | A. Saracino | S. Caputo | G Carosi | C Torti | G. Scotto | G. Punzi | L. Monno | G Angarano | L Monno | A Saracino | L Scudeller | D C Cibelli | A Tartaglia | G Punzi | S Lo Caputo | F Mazzotta | G Scotto | D. Cibelli | A. Tartaglia
[1] E. Daar. Potency and Durability of Antiretroviral Therapy , 2003, Journal of acquired immune deficiency syndromes.
[2] F. Chiodo,et al. Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems , 2004, Antiviral therapy.
[3] J. Gathe. Adherence and Potency With Antiretroviral Therapy: A Combination for Success , 2003, Journal of acquired immune deficiency syndromes.
[4] A. Antinori,et al. Selection of Antiretroviral Therapy Guided by Genotypic or Phenotypic Resistance Testing: An Open-Label, Randomized, Multicenter Study (PhenGen) , 2004, Journal of acquired immune deficiency syndromes.
[5] R. Haubrich,et al. The Correlation between Plasma Concentrations of Protease Inhibitors, Medication Adherence and Virological Outcome in HIV-Infected Patients , 2004, Antiviral therapy.
[6] B. Larder. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors , 1992, Antimicrobial Agents and Chemotherapy.
[7] J. Montaner,et al. Discrepant results in the interpretation of HIV‐1 drug‐resistance genotypic data among widely used algorithms , 2003, HIV medicine.
[8] Thomas D. Wu,et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors , 2003, AIDS.
[9] B. J. Betts,et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. , 2003, Journal of acquired immune deficiency syndromes.
[10] C. Tinelli,et al. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. , 2003, The Journal of infectious diseases.
[11] S. Staszewski,et al. Comparison of Nine Resistance Interpretation Systems for HIV-1 Genotyping , 2002, Antiviral therapy.
[12] M. Nolan,et al. Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Côte d'Ivoire. , 2003, Journal of acquired immune deficiency syndromes.
[13] Matthew J. Gonzales,et al. Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.
[14] C. Tinelli,et al. HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations. , 2004, Journal of acquired immune deficiency syndromes.
[15] Joel E Gallant,et al. Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance , 2002, Antiviral therapy.
[16] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[17] John W. Mellors,et al. A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine , 1998, Journal of Virology.
[18] Brendan Larder,et al. Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy , 2001, Journal of Virology.
[19] A. Antinori,et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) , 2002, AIDS.
[20] C. Kuiken,et al. HIV sequence databases. , 2003, AIDS reviews.
[21] Thomas Lengauer,et al. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes , 2003, Nucleic Acids Res..
[22] Bryan Chan,et al. Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..
[23] C. Tinelli,et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. , 2003, Journal of acquired immune deficiency syndromes.